The physiology of glucagon-like peptide 1

被引:2441
作者
Holst, Jens Juul [1 ]
机构
[1] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark
关键词
D O I
10.1152/physrev.00034.2006
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed in these cells. The current knowledge regarding regulation of proglucagon gene expression in the gut and in the brain and mechanisms responsible for the posttranslational processing are reviewed. GLP-1 is released in response to meal intake, and the stimuli and molecular mechanisms involved are discussed. GLP-1 is extremely rapidly metabolized and inactivated by the enzyme dipeptidyl peptidase IV even before the hormone has left the gut, raising the possibility that the actions of GLP-1 are transmitted via sensory neurons in the intestine and the liver expressing the GLP-1 receptor. Because of this, it is important to distinguish between measurements of the intact hormone (responsible for endocrine actions) or the sum of the intact hormone and its metabolites, reflecting the total L-cell secretion and therefore also the possible neural actions. The main actions of GLP-1 are to stimulate insulin secretion (i.e., to act as an incretin hormone) and to inhibit glucagon secretion, thereby contributing to limit postprandial glucose excursions. It also inhibits gastrointestinal motility and secretion and thus acts as an enterogastrone and part of the "ileal brake" mechanism. GLP-1 also appears to be a physiological regulator of appetite and food intake. Because of these actions, GLP-1 or GLP-1 receptor agonists are currently being evaluated for the therapy of type 2 diabetes. Decreased secretion of GLP-1 may contribute to the development of obesity, and exaggerated secretion may be responsible for postprandial reactive hypoglycemia.
引用
收藏
页码:1409 / 1439
页数:31
相关论文
共 340 条
[1]   Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus [J].
Ahren, B ;
Larsson, H ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :473-478
[2]   Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J].
Ahrén, B ;
Gomis, R ;
Standl, E ;
Mills, D ;
Schweizer, A .
DIABETES CARE, 2004, 27 (12) :2874-2880
[3]   The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia [J].
Ahrén, B ;
Holst, JJ .
DIABETES, 2001, 50 (05) :1030-1038
[4]  
AHREN B, 1940, AM J PHYSIOL-REG I, V286, pR269
[5]   The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem [J].
Alvarez, E ;
Martínez, MD ;
Roncero, I ;
Chowen, JA ;
García-Cuartero, B ;
Gispert, JD ;
Sanz, C ;
Vázquez, P ;
Maldonado, A ;
de Cáceres, J ;
Desco, M ;
Pozo, MA ;
Blázquez, E .
JOURNAL OF NEUROCHEMISTRY, 2005, 92 (04) :798-806
[6]   SECRETION OF GLUCAGON-LIKE PEPTIDE-1 AND REACTIVE HYPOGLYCEMIA AFTER PARTIAL GASTRECTOMY [J].
ANDREASEN, JJ ;
ORSKOV, C ;
HOLST, JJ .
DIGESTION, 1994, 55 (04) :221-228
[7]   Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells [J].
Anini, Y ;
Brubaker, PL .
ENDOCRINOLOGY, 2003, 144 (07) :3244-3250
[8]   Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice [J].
Baggio, L ;
Kieffer, TJ ;
Drucker, DJ .
ENDOCRINOLOGY, 2000, 141 (10) :3703-3709
[9]  
BALDISSERA FGA, 1984, DIABETOLOGIA, V26, P223
[10]   GLICENTIN-1-61 PROBABLY REPRESENTS A MAJOR FRACTION OF GLUCAGON-RELATED PEPTIDES IN PLASMA OF ANESTHETIZED UREMIC PIGS [J].
BALDISSERA, FGA ;
HOLST, JJ .
DIABETOLOGIA, 1986, 29 (07) :462-467